Lack of reliable laboratory parameters is the main challenge in the management of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Despite the long-known association between the HLA-DRB3*01:01 allele and human platelet antigen 1a (HPA-1a) alloimmunisation, maternal human leucocyte antigen (HLA) typing has been of little clinical value. Recently, other DRB3 allele variants have been suggested to predict the severity of FNAIT. In this nationwide population-based retrospective cohort study, we performed extensive HLA typing of 96 women, accounting for 87% of our cohort of 110 families with confirmed or possible HPA-1a-immunisation. The HLA type was compared with anti-HPA-1a levels, severity of neonatal disease and responsiveness to maternally administrated intravenous gammaglobulin (IVIG). HLA haplotypes were constructed to investigate further HLA associations. Despite significantly lower anti-HPA-1a levels in DRB3*01:01-negative women, the carrier status of this particular allele could not be used to confirm or rule out FNAIT in the absence of detectable antibodies. In the haplotype analysis, the DRB3*01:01 allele was the actual factor associated with FNAIT. No other HLA allele was shown to be of additional value as a predictor of severe FNAIT or non-responsiveness to IVIG treatment. Thus, HLA genotyping was not found useful in differentiating high-and low-risk pregnancies or in guiding antenatal treatment in affected families.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
is an uncommon (1 in 1000 pregnancies) but serious disorder caused by maternal immune response against paternal alloantigens (human platelet antigens, HPA) on fetal platelets (Burrows & Kelton, 1993; Dreyfus et al, 1997) . As the HPA1a antigen is most commonly implicated in severe FNAIT, a number of studies investigating the association between a particular human leucocyte antigen (HLA) type and the risk of developing an immune response in HPA-1a-negative women have been carried out over the last 20 years. A strong association between the HLA class-II DRB3*01:01 (DRw52a) or DQB1*02:01 and FNAIT was originally described in groups of clinically diagnosed cases (Valentin et al, 1990; L Abbe et al, 1992) and later confirmed in screening studies (Williamson et al, 1998; Maslanka et al, 2003; Turner et al, 2005; Kjeldsen-Kragh et al, 2007) . Although the negative predictive value of HLA-DRB3*01:01 in these studies was high (90-99%), indicating that HPA-1a-alloimmunisation is rare in women who lack the allele, the positive predictive value was much lower (26-35%), reducing the clinical usefulness of testing for this allele. Extensive typing of the HLA region, including seven HLA loci at the allele-level resolution, has not been carried out in the FNAIT studies performed to date.
At present, the main goal in the management of FNAIT is the prevention of severe bleeding complications in previously affected families. Non-or minimal-invasive strategies with maternally administrated intravenous gammaglobulin (IVIG) are regarded as the primary management option although a substantial proportion of fetuses (up to 55%) seem not to respond to IVIG treatment, with platelet counts remaining below 50 9 10 9 /l (Vinogard & Bussel, 2010; Kamphuis & Oepkes, 2011; van der Lugt et al, 2015) . On the other hand, current laboratory techniques may miss some clinically evident cases, leaving the subsequent pregnancies without required therapy (Bussel et al, 2005) . Although there seems to be a loose correlation between the severity of fetal thrombocytopenia and maternal anti-HPA-1a levels, using quantitation for the onset of antenatal treatment or monitoring the response to the therapy remains controversial (Williamson et al, 1998; Killie et al, 2007; Sainio et al, 2013; . Only a few studies report an association between the HLA-DRB3*01:01 type and quantitation of the anti-HPA-1a levels (Killie et al, 2008; Bertrand et al, 2011) . Recent studies on other allele variants of the HLA-DR family involved in the severity of FNAIT and the responsiveness to IVIG treatment show conflicting results (Loewenthal et al, 2013; Delbos et al, 2016) .
To overcome the main problems in everyday practice, particularly the difficulties in detecting maternal alloantibodies in clinically evident cases and in predicting fetal risk in subsequent pregnancies, we studied the maternal HLA class I and II-haplotypes in all our cases of fetomaternal HPA -1a incompatibility referred to the Finnish Red Cross Blood Service, Platelet Immunology Laboratory for neonatal thrombocytopenia between 1986 and 2010.
Methods

Subjects studied
During the study period, fetomaternal HPA-1a incompatibility was detected in 110 families with neonatal thrombocytopenia. The diagnostic criteria for confirmed FNAIT included demonstration of maternal HPA-1a antibodies with semi-quantitative monoclonal antibody immobilization of platelet antigens (MAIPA) assay (Kiefel et al, 1987) . Accordingly, HPA-1a alloimmunisation was considered confirmed in 82 and possible in 28 families. Clinical data were collected from referrals and hospital records. The pregnancy in which the condition was first diagnosed was designated the index pregnancy and maternal samples were obtained at delivery. Weekly infused IVIG (1Á0 mg/kg) was initiated in 22 women with a severely thrombocytopenic (platelet count <50 9 10 9 /l) infant in the index pregnancy (28 weeks of gestation, range 23-33 weeks) and continued until delivery (36Á5 weeks, range 31-38) in a total of 31 subsequent pregnancies. In order to ensure independent observations, only the outcome of the first subsequent pregnancy was used in the statistical analyses. Fetal blood sampling (FBS) was performed in all cases before starting the treatment, to evaluate the response and to allow safe vaginal delivery. The minimal/non-invasive strategy (decision on maternal treatment based only on sibling history/ predelivery FBS) was adopted in 2011. In order to ensure independent observation, only the outcome of the first subsequent pregnancy was used in the statistical analyses.
Laboratory methods
A total of 96 maternal samples were typed for the HLA loci A, B, C, DRB1, DRB3-5, DQA1 and DQB1 by sequence-based oligonucleotide probes (LabType, One Lambda Inc., Los Angeles, CA, USA) according to the manufacturer 0 s instructions. The HLA data were interpreted with Fusion analysis software (One Lambda inc.). The frequencies of the HLAtypes in the Finnish general population were obtained from Haimila et al (2013) . HLA haplotypes were reconstructed by Phase version 2.1 (Stephens et al, 2001) . The genotypes of 100 additional Finnish individuals were added to the analysis to improve haplotype reconstruction. The software implements a Bayesian method for inferring haplotypes from genotype data in a population sample. Anti-HPA-1a was quantified from the frozen stored samples using a quantitative MAIPA assay standardised against the World Health Organization reference serum containing 100 iu/ml (Ref 03/152) as previously described (Allen et al, 2005; Bertrand et al, 2012) . The repeatability of the assay was 8Á3%, the lower detection limit (LOD) 0Á8 iu/ml and limit of quantitation (LOQ) 1Á2 iu/ml. The results of anti-HPA-1a quantitation in the confirmed cases have been reported previously (Sainio et al, 2013) .
Statistics
Associations of two categorical variables were assessed using Fisher's exact test. Differences in medians between two groups of individuals were tested for with Mann-Whitney's U test. Analyses were performed with R 3. 
Results
Clinical and diagnostic comparison of confirmed and possible cases of FNAIT
The characteristics of the index pregnancies according to the detection of anti-HPA antibodies are presented in Table I . Maternal samples for HLA genotyping and anti-HPA-1a quantitation were available for 96 of the 110 mothers (87%). In six of the 28 cases with possible FNAIT, previously considered antibody negative with semi-quantitative MAIPA assay, the anti-HPA-1a antibody level was above the LOD of 0Á8 iu/ml (up to 1Á8 iu/ml) with quantitative MAIPA assay. Correspondingly, in four of the 84 women with confirmed FNAIT, the quantitative MAIPA assay showed an anti-HPA-1a antibody level of 0Á8 iu/ml. Altogether in three of 14 cases with a severe bleeding complication [intracranial haemorrhage (ICH) or intrauterine death (IUD)] in the index pregnancy, the anti-HPA-1a level was at or below the LOD of 0Á8 iu/ml, still leaving the diagnosis of FNAIT unconfirmed.
To establish the diagnosis in the absence of detectable antibodies, the clinical picture of the neonatal disease was studied according to the maternal HLA carrier status. All women (71/71) with a confirmed diagnosis carried the DRB3*01:01 allele (100% vs. 31% in the general population, P < 0Á001). In the group with possible diagnosis, the proportion (13/25) was still slightly higher than in the general population (52% vs. 31% P = 0Á048). The DRB3*01:01 carriers tended to have a clinically evident case of FNAIT more often than the mothers negative for this allele: neonatal platelet counts <20 9 10 9 /l, 73% vs. 9%; infants presenting petechiae 42% vs. 9%, and no other reason for neonatal thrombocytopenia 67% vs. 29%, but the differences were not statistically significant. Two infants born to DRB3*01:01-negative mothers, were diagnosed with ICH (platelet counts 22 and 32 9 10 9 /l, anti-HPA-1a levels below the LOD of 0Á8 iu/ml). Both cases had associated obstetric problems (asphyxia or instrumental vaginal delivery) that were presumed to be the cause of the ICH in combination with the thrombocytopenia.
Correlation between HLA type, anti-HPA-1a level and severity of neonatal disease Figure 1 shows the distribution of the neonatal platelet count and maternal anti-HPA-1a level according to the DRB3*01:01carrier status of the mother. The median anti-HPA-1a level at delivery was 18 iu/ml (range 0Á8-375 iu/ml) in the DRB3*01:01 positive women and below the LOD of 0Á8 iu/ml in the DRB3*01:01 negative women in all but two cases (1Á3 and 1Á7 iu/ml) (P = 0Á0002). Among the 12 DRB3*01:01 negative women, the neonatal platelet count was <50 9 10 9 /l in seven cases and <20 9 10 9 /l in one case.
Thus, the positive and negative predictive values of DRB3*01:01 carrier status for a severely thrombocytopenic (<50 9 10 9 /l) infant were 83% (95% confidence interval
[CI] 73-91%) and 42% (95% CI 15-72%), respectively. No additional value of the carrier status for DRB4*01:01 (or DRB4*01:03) or any other allele with or without the presence of the DRB3*01:01 could be drawn from this material. Of the 18 women with a pregnancy complicated by ICH or IUD (previous or index), genotyping results were available in 15 cases. For example, the proportion of DRB4*01:01 (or DRB4*01:03) carriers was not different from the corresponding proportion among the women without severe bleeding complications (30% vs. 32%) nor was any difference seen in comparison with the HLA frequencies in general population (39%).
Correlation between HLA type, anti-HPA-1a level and responsiveness to IVIG treatment Samples for genotyping were available for 21 of the 22 mothers receiving antenatal IVIG. All mothers were DRB3*01:01 positive. In order to ensure independent observations, only the outcome of the first subsequent pregnancy was used in the statistical analyses. The median platelet counts from the previous pregnancy, and fetal (before any treatment was given) and neonatal (at delivery) platelet counts from the subsequent pregnancy are presented in Fig 2. Eleven of the 22 fetuses (50%) did not respond to the treatment, with platelet counts remaining <50 9 10 9 /l (<20 9 10 9 /l in three cases). On the other hand, 11 of the 22 fetuses (50%) responded well, with a neonatal platelet count of >50 9 10 9 /l, and six of them (29%) had an excellent response (platelet count >100 9 10 9 /l). The individual responsiveness to antenatal IVIG treatment according to HLA type is presented in Fig 3. The presence of DRB4*01:01 (or DRB4*01:03) in addition to In this study, 63% of the infants born to mothers carrying both alleles achieved platelet counts of over 50 9 10 9 /l and 50% had platelet counts > 100 x10 9 /l, compared to the corresponding rates of 50% and 8% of the infants born to mothers carrying only DRB3*01:01 (differences not statistically significant). The maternal anti-HPA-1a antibody level, obtained at the second trimester before treatment, ranged from 0Á8 to 283 iu/ml. The median antibody level was 27 iu/ml (range 0Á8-383) for the responders and 21 iu/ml (range 4Á2-126) for the non-responders. Cut-off levels that could predict response to the therapy could not be drawn from this material. Two of the non-responders were diagnosed with ICH (at 26 and 31 weeks of gestation); the respective antibody levels were 129 and 49 iu/ml. These cases have been reported before (Sainio et al, 2013) .
HLA haplotype analysis
In addition, HLA haplotypes were constructed to scrutinize possible further associations in the HLA region (Table II) . The haplotype HLA-A*01:01-C*07:01-B*08:01-DRB3*01:01-DRB1*03:01-DQA1*05:01-DQB1*02:01 was the most frequent, with 70% (50/71) of the confirmed FNAIT cases carrying it or part of it (including at least all the class II alleles). The frequency of this haplotype (or part of it) is 9% in Caucasoids with European background (Gragert et al, 2013) . The next frequent (25%, 18/71) haplotype in this study population was DRB3*01:01-DRB1*13:01-DQA1*01:03-DQB1*06:03 including only HLA class II loci; this haplotype frequency is 3% in Caucasoids. The homozygotes were not overrepresented; only one (DRB3) allele or haplotype is enough to predispose to FNAIT. Only five mothers did not carry either of these haplotypes; they were all DRB3*01:01 positive but there were no further significant similarities in their HLA haplotypes.
Discussion
Lack of reliable laboratory parameters and non-invasive methods to guide antenatal treatment is still the main challenge for the platelet immunology laboratories and clinicians that manage pregnancies complicated by FNAIT. Encouraged by the new promising results regarding the molecular background of FNAIT, we performed extensive HLA-typing at a high resolution level for seven HLA loci in 96 women, accounting for 87% of our cohort of 110 families with confirmed or possible HPA-1a-immunisation. In addition, we reconstructed HLA haplotypes to determine their predictive value in assorting severe cases of FNAIT. The main finding was that, despite significantly lower anti-HPA-1a levels in DRB3*01:01 negative women, the carrier status for this particular allele could not be used to confirm or rule out FNAIT in the absence of detectable antibodies. Furthermore, the DRB4*01:01 allele, or any other HLA-type, was not be shown to be of additional value as a predictor of severe FNAIT or non-responsiveness to IVIG treatment in our cohort.
In cases of undetectable alloantibodies, the absence of maternal DRB3*01:01 has been suggested to make the diagnosis of FNAIT highly unlikely . In our cohort, even with the quantitative MAIPA assay, the antibody remained undetected in almost 13% of cases. Thus the diagnosis remained unconfirmed not only in several cases presenting typical FNAIT but also in two of the 14 cases with ICH or IUD. Not quite unexpectedly, 52% of the mothers in the group of possible FNAIT were carriers of the DRB3*01:01 allele, indicating that the diagnosis could be more likely in such cases. However, the group of infants with DRB3*01:01 negative mothers included two cases of ICH (platelet counts 22 and 32 9 10 9 /l, anti-HPA-1a antibodies <0Á8 iu/ml). Even in the presence of other reasons presumed to be cause of the thrombocytopenia, ruling out FNAIT in such severe cases and following the rule of thumb "no antibody -no treatment" is particularly challenging for the obstetricians taking care of the subsequent pregnancies in these families. Interestingly, Peterson et al (2013) suggest that women lacking the DRB3*01:01 allele may be predisposed to produce low avidity HPA-1a antibodies that are undetectable by conventional methods. Indeed, in our cohort anti-HPA-1 antibody levels were significantly higher in DRB3*01:01 positive women than in DRB3*01:01 negative women. Furthermore, Loewenthal et al (2013) suggested that the presence of DRB4*01:01 with DRB3*01:01 increases the risk and severity of FNAIT. Unfortunately that very promising finding could not be repeated in our study, where the carrier status for DRB4*01:01 or any other allele was not shown to have any additional value as a predictor of severe FNAIT. We also demonstrated that the combination of both alleles did not affect the anti-HPA-1a-levels, a finding not reported in the Israeli study. Thus, even though Loewenthal et al (2013) proposed a very elegant model for the molecular basis of the effect of the HLA type, it is more likely that these discrepant observations are due to different genetic backgrounds in different populations or the small sample size in both studies.
In the largest screening study from Norway, approximately 10% of the 170 immunised women were DRB3*01:01 negative with a mean antibody level of only 0Á4 (AE0Á3) iu/ml, but only two of them gave birth to a moderately thrombocytopenic infant . The latter finding is in contrast to our study, where seven of the 12 DRB3*01:01 negative women gave birth to a severely thrombocytopenic infant (platelet count <50 9 10 9 /l). Moreover, a cut-off level for severe thrombocytopenia similar to the ≤3Á0 iu/ml mentioned in the Norwegian study had a significantly lower negative predictive value in our cohort (33% vs. 95%). These discrepant results may be due to the timing of maternal sampling but may also result from difficulties with the quantitative MAIPA assay itself. Our study also clearly demonstrates that, particularly at low anti-HPA-1a antibody levels, the clinical picture may be very heterogeneous, ranging from non-affected to the typical clinical picture of FNAIT and even to severe bleeding complications. In screening programmes, having a reliable laboratory test with a carefully measured LOD, LOQ and uncertainty of the results is crucial to avoid a significant number of unnecessary interventions with long-lasting consequences. The possible role of HLA genotyping in such programmes needs to be studied. The optimal therapy in the subsequent pregnancies of previously affected families is still uncertain. Today, maternally administered IVIG is generally considered to be highly successful in preventing ICH, the true goal of antenatal management, even when failing to keep the fetal platelet count within a safe range. In keeping with previous studies (Vinogard & Bussel, 2010; Kamphuis & Oepkes, 2011; van der Lugt et al, 2015) , the response rate to IVIG in our study was only 50%, when defined as neonatal platelet counts remaining <50 9 10 9 /l. Furthermore, two of these non-responders were diagnosed with ICH, a finding also reported before (Berkowitz et al, 2006) . However, no conclusion on the effectiveness of IVIG therapy in preventing ICH can be drawn on the basis of our study, which is clearly underpowered for that, as are most other studies. Even with platelet counts only serving as surrogate markers of severe bleeding complications, complex algorithms have been reported to improve the predictive value of maternal antibody level for IVIG therapy failure . However, clinical application of a test with a sensitivity of 76% and specificity of 79%, as described in the French study, is very difficult in treatment programmes where antenatal treatment is given only in the case of a severely thrombocytopenic sibling. A threshold of 28 iu/ml introduced in the French study for severe fetal thrombocytopenia proved to have very disappointing positive and negative predictive values (87% vs. 50% and 77% vs. 40%, respectively) in our cohort even though measurements were similarly determined before 28 weeks and before any treatment. In the aforementioned Israeli study, Loewenthal et al (2013) suggested that compound heterozygosity for DRB4*01:01 and DRB3*01:01 reduces the success of IVIG treatment based on their finding that only 17% of the infants born to women carrying both alleles achieved platelet counts of over 100 9 10 9 /l, in comparison to 67% of the newborns carrying only DRB3*01:01. Our results, with the corresponding rates of 50% and 8%, respectively, were more in line with a very recent French study (Delbos et al, 2016) , but similarly, none of the figures were statistically significant. Finally, although the haplotype HLA-A*01:01-C*07:01-B*08:01-DRB3*01:01-DRB1*03:01-DQA1*05:01-DQB1*02:01 was overrepresented in the confirmed cases, six other haplotypes were also detected in our cohort. The allele DRB3*01:01 is the actual factor associated with FNAIT. The abovementioned haplotype is the most frequent haplotype in Caucasoids with European background and DRB3*01:01 is present in a dozen HLA-haplotypes in the general population.
In conclusion, despite the long-known association between DRB3*01:01 and HPA-1a-alloimmunisation, genotyping other HLA alleles is unlikely to be useful in the differentiation of the high-and low-risk pregnancies or in the guidance of antenatal treatment in the affected families. Maternal immunogenetic factors should, however, be actively studied. Understanding of the molecular basis and natural history of FNAIT is essential for all future management strategies, including the development of a prophylactic anti-HPA-1a.
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